Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.34 |
| ▸ | CHRNG | P07510 | 1/20 | 0.34 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.34 |
| ▸ | CHRND | Q07001 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2170851 | 1.00 | HSD17B2 (0.40) | HSD17B2KMT2AALDH1A1ATML3MBTL1 | |
| SCHEMBL17937285 | 0.91 | KMT2A (0.38) | HSD17B2KMT2AALDH1A1ATML3MBTL1 | |
| SCHEMBL31037751 | 0.85 | L3MBTL1 (0.37) | HSD17B2KMT2AALDH1A1L3MBTL1CYP2D6 | |
| SCHEMBL20538709 | 0.83 | HTR2C (0.42) | ATM | |
| SCHEMBL19287188 | 0.83 | HTR2C (0.42) | ATM | |
| SCHEMBL8074350 | 0.83 | HTR2C (0.42) | ATM | |
| SCHEMBL31000581 | 0.71 | HTR2C (0.47) | KMT2AALDH1A1CYP3A4CYP2D6MAPK1 | |
| SCHEMBL7555828 | 0.70 | ALDH1A1 (0.36) | HSD17B2ALDH1A1L3MBTL1CYP3A4CYP2C19 | |
| SCHEMBL20833180 | 0.69 | CHRNA1 (0.41) | HSD17B2KMT2AALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL2571281 | 0.69 | HSD17B2 (0.45) | HSD17B2KMT2AALDH1A1ATMCHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10220039-B2 | Method of treating polycystic kidney diseases with ceramide derivatives | GENZYME CORPORATION (US) | 2019-03-05 | — | — | US | disclosed |
| EP-2550965-B1 | Ceramide derivatives for treating polycystic kidney disease | GENZYME CORP (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-2594563-B1 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | GENZYME CORP (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2018-04-05 | — | — | US | disclosed |
| EP-2209473-B1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORP (US) | 2017-11-22 | — | — | EP | disclosed |
| US-20170258802-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION | 2017-09-14 | — | — | US | disclosed |
| US-9745294-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9744153-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| EP-2320886-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE | GENZYME CORP (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20160338996-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2016-11-24 | — | — | US | disclosed |
| US-20120322786-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2012-12-20 | — | — | US | disclosed |
| US-8309593-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2012-11-13 | — | — | US | disclosed |
| US-8304447-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2012-11-06 | — | — | US | disclosed |
| US-20110184021-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2011-07-28 | — | — | US | disclosed |
| US-20110166134-A1 | Glucosylceramide Synthase Inhibition For The Treatment Of Collapsing Glomerulopathy And Other Glomerular Disease | GENZYME CORPORATION | 2011-07-07 | — | — | US | disclosed |
| US-20100298317-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION | 2010-11-25 | — | — | US | disclosed |
| EP-2209473-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | Genzyme Corporation (US) | 2010-07-28 | — | — | EP | disclosed |
| EP-2167485-A2 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009045503-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2008150486-A2 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10220039-B2 | Method of treating polycystic kidney diseases with ceramide derivatives | SGMS1, SGMS2, CERS2 | HSD17B2 543/4885KMT2A 2267/4885ALDH1A1 2203/4885 |
| US-20110184021-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GBA1, GBA2, ASAH2 | HSD17B2 742/4885KMT2A 1338/4885ALDH1A1 1211/4885 |
| US-20120322786-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, ASAH2 | HSD17B2 742/4885KMT2A 1338/4885ALDH1A1 1211/4885 |
| US-20170258802-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | SGMS1, SGMS2, CERS2 | HSD17B2 543/4885KMT2A 2267/4885ALDH1A1 2203/4885 |
| US-20110166134-A1 | Glucosylceramide Synthase Inhibition For The Treatment Of Collapsing Glomerulopathy And Other Glomerular Disease | GBA1, UGCG, GBA2 | HSD17B2 1059/4885KMT2A 3993/4885ALDH1A1 3569/4885 |
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | ASAH2, GBA1, GAA | HSD17B2 619/4885KMT2A 1937/4885ALDH1A1 961/4885 |
| US-20160338996-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GBA1, GBA2, ASAH2 | HSD17B2 742/4885KMT2A 1338/4885ALDH1A1 1211/4885 |
| US-20100298317-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | SGMS1, SGMS2, CERS2 | HSD17B2 543/4885KMT2A 2267/4885ALDH1A1 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.